Kornimate/medical-research-clean huggingface dataset:
the effect of foot and ankle exercise on pain and quality of life in patients with diabetic neuropathy

Conditions: Diabetic Neuropathy, Painful

Summary: the study will be carried out to determine the effect on pain and quality of life between the groups that received and did not receive foot and ankle exercise training.

in the literature, in patients with diabetic neuropathy who received foot and ankle exercise training; it is observed that it reduces the level of pain and increases the quality of life. foot and ankle exercise training given to the participants improved blood circulation, improved foot-ankle range of motion, increased foot muscle strength and function, improved diabetic neuropathy symptoms, redistributed plantar pressure during movement, improved sensitivity, and was effective in maintaining balance; it is thought that participants can reduce pain and improve their quality of life with foot and ankle exercise training. while there are studies examining the effect of non-pharmacological interventions such as spa treatment and pulse electromagnetic field therapy in patients with diabetic neuropathy in our country, no study has been found examining the effect of foot and ankle exercise training on pain and quality of life in patients with diabetic neuropathic pain. it is thought that the results of the research will be beneficial in symptom management and improve quality of life in addition to pharmacological treatment.

Eligibility criteria:
inclusion criteria: * 18 years and over, * having been diagnosed with type 2 diabetes for at least one year, * diagnosed with diabetic peripheral neuropathy for at least 6 months by emg by a neurologist, * individuals with diabetes mellitus with neuropathic pain who score 12 or higher on the s-lanns (self-leeds assessment of neuropathic symptoms and sign) pain scale, * visual analogue scale (vas) value to be at least 1, * receiving medical treatment for diabetic neuropathy, * did not receive physical therapy and non-pharmacological treatment during the research period, * having no physical and mental problems that will prevent communication, * having blood glucose meters at home, * individuals with smart device use, exclusion criteria: * peripheral vascular complications due to diabetes or another etiology, * having a history of surgery on the knee, ankle and hip and indication for surgery during the intervention period, * those who cannot communicate on the phone (with hearing problems), * having nephropathy, retinopathy and diabetic foot, * neurological diseases (stroke, cerebrovascular diseases, epilepsy) and serious musculoskeletal problems (rheumatoid arthritis, osteoarthritis) * neurocognitive disorder (alzheimer's disease, dementia), * not taking any physical therapy during the intervention period, * patients with deep vein thrombosis, femur fractures, surgical conditions, open wounds

Keywords: diabetic neuropathic pain exercise foot and ankle pain quality of life
efficacy of intraductal radiofrequency ablation in combination with metallic biliary stenting in advanced hilar cholangiocarcinoma

Conditions: Hilar Cholangiocarcinoma; Biliary Obstruction

Summary: the study aim to evaluate the efficacy of intraductal radiofrequency ablation for unresetable hilar cholangiocarcinoma in addition to biliary stenting. the patient would be randomized into 1:1 ratio of conventional group who received biliary stenting alone, and rfa group who receive intraductal rfa before biliary stenting. immediate complications as well as long term stent patency and patient survival would be studied.

study design: randomized single-blind control trial study population: patient with unresectable hilar cholangiocarcinoma with obstructive jaundice who need hilar biliary stenting primary endpoint: biliary stent patency time secondary endpoint: patient survival intervention 1. recruited patients randomly assigned into 2 groups, conventional and rfa group by sealed enveloped 2. all patients receive endoscopic biliary stenting. those in rfa group receive rfa before biliary stent. 3. monitor for adverse event during hospitalization and during follow up 4. follow up as outpatient in 4-weekly interval with monitoring of serum liver function test as routine

Eligibility criteria:
inclusion criteria: * hilar cholangiocarcinoma diagnosed by imaging or pathology * considered unresectable or unfit for surgery * presence of obstructive jaundice need endoscopic biliary drainage exclusion criteria: * history of unremovable metallic biliary stent placement * severe biliary stricture that the instrument was unable to pass through * unfit for endoscopic under conscious sedation * loss to follow up and loss contact within 6 months after intervention

Keywords: hilar cholangiocarcinoma biliary obstruction radiofrequency ablation
effects of once and twice daily dosing regimen of ertugliflozin (pf-04971729, mk-8835) in participants with type 2 diabetes (mk-8835-040)

Conditions: Diabetes Mellitus, Type 2; Adult

Summary: this is a phase 1 randomized, double-blind, sponsor open, 4 arm, 2 way cross-over study using 2 cohorts. the objective of the study is to evaluate the pharmacodynamics (pd) effects and the pharmacokinetic (pk) of single day dosing of 2 mg and 4 mg doses of ertugliflozin (ertu, pf-04971729/mk-8835) each administered once vs twice daily (morning \[am\] and evening \[pm\]) in adults with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * participants with type 2 diabetes mellitus, either treatment-naïve or on up to 2 acceptable oral anti-diabetes drugs for at least 8-weeks prior to study. exclusion criteria: * participants with type 1 diabetes mellitus, participants with stroke, unstable angina, heart attack in last 6-months, uncontrolled blood pressure.
post-stroke seizure and epilepsy following thrombolytic therapy

Conditions: Post-stroke Seizure; Post-stroke Epilepsy; Thrombolytic (t-PA) Treatment

Summary: this retrospective cohort study was conducted by reviewing the records of consecutive patients referred to bu ali sina hospital from 2016 to 2023, who were hospitalized with a diagnosis of ischemic stroke. the records of all patients treated with intravenous alteplase during the above period were extracted, and the relevant characteristics were recorded in a questionnaire. in each year, patients with ischemic stroke who were not treated with alteplase but were hospitalized at the bu ali center were selected in a similar number to patients who received alteplase in the same year, and the relevant information was extracted from their records and recorded in a questionnaire. the incidence of post-stroke seizures and epilepsy was determined in both groups, and the factors associated with their incidence were studied and compared.


Eligibility criteria:
inclusion criteria: * diagnosis of ischemic stroke * treatment with iv alteplase exclusion criteria: * history of epilepsy * taking antiseizure medications * unavailable patients * unreliability of recorded patients' files
prevention of taxane-associated acute pain syndrome with etoricoxib

Conditions: Pain Syndrome

Summary: a phase ii randomized clinical trial was conducted to determine whether etoricoxib could prevent or ameliorate the incidence and/or severity of docetaxel-induced acute pain syndrome. we also aimed to determine if there are any improvement of the late-onset peripheral neuropathy as well as quality of life with prophylactic etoricoxib for breast cancer patients who receive docetaxel chemotherapy.

docetaxel plays a key role in reducing the recurrence of early-stage breast cancer as well as improving survival outcomes of advanced breast cancer patients, but it causes a variety of adverse events, including myalgia and arthralgia, peripheral neuropathy, febrile neutropenia, and hypersensitivity reactions and so on. the myalgia and arthralgia induced by docetaxel, which have been together referred to as taxane-associated acute pain syndrome (t-aps), were reported to occur in 3.6% to 70% of patients, and the symptoms usually occurred 24-48 hours after docetaxel infusion and lasted for 3-5 days. previous studies found that patients who experienced myalgia and arthralgia due to docetaxel administration were more likely to have chronic peripheral neuropathy, which supported that t-aps could be a form of neurologic toxicity. t-aps may significantly influence patients' sleep and daily life, and even caused discontinuation of chemotherapy. therefore, it is clinically meaningful to explore some prophylactic drugs for the t-aps. previous studies had used glutamine, corticosteroids, shakuyaku-kanzo-to (a japanese herb), and gabapentin to prevent paclitaxel-induced myalgia and arthralgia, but failed to provide enough evidence for clinical practice. etoricoxib, a selective cox-2 inhibitor, is a nonsteroidal anti-inflammatory drug (nsaid) that has showed comparable efficacy in acute and chronic pain, with fewer gastrointestinal (gi) adverse events compared with traditional nsaids. therefore, we conducted a phase ii randomized clinical trial to investigate whether etoricoxib could prevent or ameliorate the incidence and/or severity of docetaxel-induced acute pain syndrome. we also aimed to determine if there are any improvement of the late-onset peripheral neuropathy as well as quality of life with prophylactic etoricoxib for breast cancer patients who receive docetaxel chemotherapy.

Eligibility criteria:
inclusion criteria: * signed informed consent * age ≥18 years * stage i-iii breast cancer * ecog 0-2 * received docetaxel-containing chemotherapy exclusion criteria: * existed any chronic pain or peripheral neuropathy * prior history of gastrointestinal bleeding or ulcer * long-term history of receiving oral corticoids, nonsteroid anti-inflammatory drugs (nsaids) or anti-histamines * allergies to nsaids or aspirin * blood creatinine level exceeds 1.5 times of the upper limit of normal range

Keywords: breast cancer docetaxel etoricoxib acute pain syndrome peripheral neuropathy
mbi in generation z nursing students during clinical practicum

Conditions: Mental Health; Anxiety; Depression; Resilience

Summary: this study is a randomized clinical trial design. the research subjects were the internship nursing students in the nursing department of a nursing school in the northern taiwan. the experimental group received mindfulness-based stress reduction intervention, while the control group received routine care with weekly line care messages from class instructors. both groups took the post-test before the internship (t0), during the internship (t1), after the internship (t2), and one month after the internship (t3), a total of 4 times. the contents include psychological well-being scale; anxiety, depression, stress scale and mental scale.

students need to learn a lot of new medical knowledge and skills during clinical internships, which requires time and effort. however, this kind of learning pressure may put a considerable burden on nursing students, especially anxiety, depression, and stress. through effective coping strategies, students can improve their confidence in facing clinical situations. mindfulness-based stress reduction is a stress-reduction method based on mindfulness meditation. it can relieve the physical and mental stress and anxiety of high-stress people, improve sleep quality, chronic fatigue, and enhance concentration. the purpose of this study is to explore the effectiveness of mindfulness-based stress reduction intervention on anxiety, depression, and stress in clinical practice of nursing students. this study adopted a randomized clinical experimental research design. nursing students from a fifth-level college in the north were selected as the research subjects. a total of 80 people were recruited. nursing intern students who were willing to participate in the study were randomly assigned and divided into an experimental group of 40 people and a control group. 40 people, the experimental group participated in the mindfulness-based stress reduction course for 8 weeks. the mindfulness-based stress reduction course was led by a certified mindfulness-based stress reduction teacher, once a week, 2 hours each time, for 8 consecutive weeks; the students in the control group received weekly line care messages from the class instructor. research tools include the general health status scale, anxiety and depression stress scale, and mental resilience scale. the data were analyzed using spss20.0 for windows.

Eligibility criteria:
inclusion criteria: * (1) nursing students during clinical practicum (2) clear consciousness. exclusion criteria: -(1) students diagnosed with schizophrenia, anxiety, depression or affective psychosis. (2)taking anti-anxiety medicine treatment or anti-depressant medicine treatment.

Keywords: mindfulness-based stress reduction generation z nursing students
right side of heart function after lung surgery

Conditions: Lung Cancer; Ventricular Failure, Right

Summary: the purpose of this study is explore the impact of lung cancer surgery on the function of the right side of the heart.

lung cancer is the second most common cancer in the uk. in suitable cases the best chance of cure is surgical resection. studies suggest that lung resection is associated with right ventricular (rv) dysfunction, predisposing to complications and post-operative dyspnoea. studies of rv function following lung resection have been hampered by the limitations of the techniques used. in addition the mechanism of rv dysfunction has remained elusive. in this prospective observational study the rv response to lung resection will be characterised by sequential assessment of right ventricular ejection fraction (rvef) measured using cardiovascular magnetic resonance (cmr). cmr is non-invasive, involves no ionising radiation and due to its high spatial resolution is the gold standard for assessing rv volumes. comprehensive cmr and echocardiographic assessment of the pulmonary vascular - rv axis will allow us to interpret peri-operative changes in rvef in the context of rv contractility and loading indices. in addition, contemporaneous blood samples will be taken for measurement of biomarkers of myocardial and endothelial dysfunction and systemic inflammation. with increased understanding of the mechanisms involved, it may be possible to prevent rv dysfunction; reducing complication rates, hospital stay and costs and ameliorating long term dyspnoea.

Eligibility criteria:
inclusion criteria: 1. provision of informed consent 2. age \>16 years 3. planned elective lung resection by lobectomy exclusion criteria: 1. pregnancy 2. on-going participation in any investigational research which could undermine the scientific basis of the study 3. contraindications to magnetic resonance imaging: i. cardiac pacemaker, artificial heart valve, neurostimulator, cochlear implant ii. aneurysm clips iii. metal injuries to the eye iv. loose metal in an part of the body 4. wedge / segmental / sub-lobar lung resection 5. pneumonectomy 6. isolated right middle lobectomy

Keywords: lung cancer ventricular function, right
evaluating the effect of nutritional supplementation on growth of short and lean adolescents girls

Conditions: Growth Problem; Low Weight

Summary: study design: double blind, randomized, placebo controlled study. participants will be randomly assigned either to the intervention group or the placebo control group. randomization for the two study groups will be made in a ratio of 1:1. the primary objective of the study is to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean female adolescents on weight standard deviation score (sds) and height sds the secondary objectives of the study are to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean female adolescents on bmi sds, growth velocity, time to puberty, quality of life and self-esteem the study will continue for 6 months of intervention versus active placebo, with additional optional 6 months (an extension period), in which participants at both groups, the intervention and the placebo, will be offered to continue their participation in the study with the study supplement. all analyses of the effect's on primary and secondary outcome measurements will take into account the consumption rate of the study formula/placebo


Eligibility criteria:
inclusion criteria: * girls aged ≥9 years old * prepubertal - tanner stage 1. (gonadarche) breast at tanner stage 1) * height and weight ≤ 10th percentile for age and gender. * height-sds ≥ -2.5 sds * bmi-sds\>-2 sds * low proportion between weight and height * signing inform consent forms exclusion criteria: * diagnosis of growth hormone (gh) deficiency or treatment with gh * any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardiac, renal or pulmonary problems * any known gastrointestinal disease including malabsorption * any known organic reason for growth retardation * any chronic treatment with medication that might affect appetite, weight or growth (for example ssri's).

Keywords: growth low weight low height nutritional supplementation
arq 501 in combination with gemcitabine in subjects with pancreatic cancer

Conditions: Pancreatic Cancer; Adenocarcinoma

Summary: the study will document the safety and efficacy of the combination of arq 501 and gemcitabine in patients with treatment-naïve, unresectable, metastatic pancreatic adenocarcinoma.

this is a single-arm, non-randomized study of arq 501 in combination with gemcitabine in adult patients with treatment-naïve, unresectable, metastatic pancreatic adenocarcinoma. the study objectives are: primary objective: * assess the overall response rate (orr) of patients treated with arq 501 in combination with gemcitabine. secondary objectives: * determine time to tumor progression (ttp) of patients treated with arq 501 in combination with gemcitabine * further characterize the safety of arq 501 in combination with gemcitabine

Eligibility criteria:
inclusion criteria: * have a pathologically confirmed diagnosis of unresectable, metastatic pancreatic adenocarcinoma * be treatment-naïve. * have measurable disease per recist criteria. * be ≥18 years old. * have a karnofsky performance status (kps) of ≥70%. * have an estimated life expectancy of ≥12 weeks. * be male or a non-pregnant, non-lactating female patient. patients who are fertile agree to use an effective barrier method of birth control (e.g., latex condom, diaphragm, or cervical cap) to avoid pregnancy. * have a negative serum or urine pregnancy test within 7 days prior to the first dose of study drug (if patient is a female of childbearing potential). * sign a written informed consent form. * have adequate organ function as indicated by acceptable laboratory values obtained within 7 days prior to the first dose of study drug. exclusion criteria: * have received any prior therapy for the treatment of their pancreatic malignancy (including chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or investigational). * have an active, uncontrolled systemic infection considered opportunistic, life threatening or clinically significant at the time of treatment. * are pregnant or lactating. * have a psychiatric disorder(s) that would interfere with consent, study participation, or follow-up. * have any other severe concurrent disease, which, in the judgment of the investigator, would make the patient inappropriate for entry into this study. * have symptomatic or untreated central nervous system (cns) metastases. * have a known hypersensitivity to gemcitabine.

Keywords: cancer solid tumor advanced solid tumor pancreas pancreatic cancer cancer of the pancreas
a study to investigate the magnitude and duration of response of mk0954 compared to placebo in patients with hypertension (0954-021)(completed)

Conditions: Hypertension

Summary: the purpose of this study was to evaluate the magnitude and durations of the antihypertensive effects of losartan using ambulatory blood pressure monitoring (abpm), and to evaluate the safety of losartan 50 and 100 mg doses compared to placebo.


Eligibility criteria:
inclusion criteria: * non-black men and women with mild to moderate hypertension and within 30% of their ideal body weight * patient is in good general health * blood pressure at time of randomization is 95-115 mm hg exclusion criteria: * secondary hypertension or history of malignant hypertension * history of stroke * history of myocardial infarction * atrial flutter or atrial fibrillation * history of congestive heart failure * patient taking major psychotropic agent or anti-depressant * patient regularly uses nsaids or high dose aspirin * known positive test for hiv/aids or hepatitis b * patient is being treated for acute ulcer disease * prior exposure to losartan * actively treated diabetes mellitus * history of chronic liver disease * actively treated diabetes mellitus * any known bleeding or platelet disorder * absence of one kidney * women of childbearing potential * alcoholism or drug addiction
transcranial doppler ultrasound monitoring during flow-diverter embolization

Conditions: Intracranial Aneurysm; Aneurysm, Intracranial; Giant Intracranial Aneurysm

Summary: flow diverters have been approved since 2012 for the treatment of large, wide neck intracranial aneurysms. these devices have been associated with embolic events which cause blockage in a blood vessel and can result in long term complications. one possible cause of these events is the formation of small emboli during placement of the device.

flow diverters have been developed to treat intracranial aneurysms. embolisms have occurred in a small percentage of patients which can result in long term complications including stroke, hemorrhage, and even death. the formation of microemboli during the insertion of the device has not been evaluated. during insertion, there is significant disruption of blood flow and this may be a source of intracranial microemboli. this study will use transcranial doppler ultrasound (tcd) to evaluate the blood flow during the placement of flow diverters to try to determine why these embolic events occur.

Eligibility criteria:
inclusion criteria: * adult subjects 18 years of age and older * non-pregnant * diagnosis of intracranial aneurysm that will be clinically treated with a flow diverter exclusion criteria: * pregnant